Interventions du FILO à l'ASH 2024 dans le domaine de la LLC

ERADIC

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Communication Orale présentée par Anne-Sophie MICHALLET

Result Type: Paper
Number: 584
Presenter: Anne-Sophie Michallet
Program: Oral and Poster Abstracts
Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Mutations, Prognosis and MRD in CLL
Time and Location:8 Déc 2024 12:00-13:30

PREVENE

Preemptive Therapy with Venetoclax for High-Risk Stage a CLL Patients: First Analysis of Prevene, a Phase II Trial of the Filo Group

Poster présenté par Vincent LEVY

Result Type: Paper
Number: 3256
Presenter: Vincent Levy
Program: Oral and Poster Abstracts
Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II
Time and Location: 8 Déc 2024 18:00-20:00

Meta-Analyse

Prevalence of BTK and PLCG2 Mutations in BTK Inhibitor Treated CLL Patients Who Experience Disease Progression: A Meta-Analysis

Poster présenté par Stefano MOLICA (Hull University Teaching Hospitals NHS Trust, Hull, UK)

Result Type: Paper
Number: 4630
Presenter: Stefano MOLICA
Program: Oral and Poster Abstracts
Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III
Time and Location: 9 Déc 2024 18:00-20:00